Literature DB >> 12915613

Modified Fibonacci search.

George A Omura.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12915613     DOI： 10.1200/JCO.2003.99.058

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

Authors:  Amita Patnaik; Kyriakos P Papadopoulos; Anthony W Tolcher; Muralidhar Beeram; Saïk Urien; Larry J Schaaf; Sanaa Tahiri; Tanios Bekaii-Saab; François M Lokiec; Keyvan Rezaï; Aby Buchbinder
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-30       Impact factor: 3.333

2.  Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer.

Authors:  Yihebali Chi; Jianliang Yang; Sheng Yang; Yongkun Sun; Bo Jia; Yuankai Shi
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

3.  What does a modified-Fibonacci dose-escalation actually correspond to?

Authors:  Nicolas Penel; Andrew Kramar
Journal:  BMC Med Res Methodol       Date:  2012-07-23       Impact factor: 4.615

4.  Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.

Authors:  Sanjay Goel; Kavita Desai; Sirisha Karri; Radharani Gollamudi; Imran Chaudhary; Anca Bulgaru; Andreas Kaubisch; Gary Goldberg; Mark Einstein; Fernando Camacho; Sharyn Baker; Sridhar Mani
Journal:  Invest New Drugs       Date:  2006-12-30       Impact factor: 3.651
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.